

September 3, 2021

## Santen to Present Latest Data including STN1012700 (DE-127) at APAO 2021

Santen Pharmaceutical Co., Ltd. (Head Office in Osaka, hereinafter "Santen") announced today that some publications related to STN1012700 (DE-127), a non-selective muscarinic antagonist, etc. will be presented at the 36<sup>th</sup> virtual Asia-Pacific Academy of Ophthalmology Congress (APAO 2021; <a href="https://2021.apaophth.org/">https://2021.apaophth.org/</a>) from September 5 to 11, 2021.

A Phase 2/3 study of STN1012700 has been conducted to investigate for slowing myopia progression in children in Japan and a Phase 1 study in China is being planned for FY2021. The recent Phase 2 study data of STN1012700 from APPLE study in Asia will be presented at APAO 2021.

## Presentation topics

Session	Date and Time	Title
Pediatric Ophthalmology	Sept 5–11	Pupil Size Analysis and Efficacy of DE-127 (0.0025%,
and Strabismus	(on-demand	0.005%, 0.01%) versus Placebo in Slowing Myopia
(Abstract ID: 201344;	ePoster)	Progression: The Randomized Phase 2 APPLE Study
Presenting author: Chia)		
Pediatric Ophthalmology	Sept 5–11	Efficacy of DE-127 in Slowing Myopia Progression
and Strabismus	(on-demand	According to Baseline Spherical Equivalent in the
(Abstract ID: 201350;	ePoster)	Phase 2 Randomized APPLE Study
Presenting author: Chia)		
Glaucoma and glaucoma	Sept 5–11	Outcomes of MicroShunt Implantation vs
surgery	(on-demand	Trabeculectomy Based on Visual Field Severity: 1-
(Abstract ID: 202170;	ePoster)	Year Results from a Randomized, Multicenter Study
presenting author:		
Grover)		
Glaucoma and glaucoma	Sept 5–11	A 2-year Pooled Analysis of the MicroShunt in Patients
surgery	(on-demand	with Primary Open-angle Glaucoma
(Abstract ID: 202171;	ePoster)	
presenting author: Batlle)		

In addition, Glaukos Corporation (San Clemente, CA, U.S.) is responsible for developing and selling STN2000100 (DE-128, MicroShunt) in the Americas, Australia, and New Zealand (press release on May 19, 2021; <a href="https://www.santen.com/en/news/20210519-1.pdf">https://www.santen.com/en/news/20210519-1.pdf</a>).

Contact:

Investor Relations Group
Santen Pharmaceutical Co., Ltd.

E-mail: <u>ir@santen.com</u>